Article Information
History
- December 29, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Corine H. GeurtsvanKessel1,*,
- Daryl Geers1,†,
- Katharina S. Schmitz1,†,
- Anna Z. Mykytyn1,†,
- Mart M Lamers1,†,
- Susanne Bogers1,
- Lennert Gommers1,
- Roos S.G. Sablerolles2,
- Nella N. Nieuwkoop1,
- Laurine C. Rijsbergen1,
- Laura L.A. van Dijk1,
- Janet de Wilde1,
- Kimberley Alblas1,
- Tim I. Breugem1,
- Bart J.A. Rijnders3,
- Herbert de Jager4,
- Daniela Weiskopf5,
- P. Hugo M. van der Kuy2,
- Alessandro Sette5,6,
- Marion P.G. Koopmans1,
- Alba Grifoni5,$,
- Bart L. Haagmans1,$,* and
- Rory D. de Vries1,$,*
- 1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
- 2Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands
- 3Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
- 4Department of Occupational Health Services, Erasmus MC, Rotterdam, Netherlands
- 5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
- 6Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA
- ↵*Corresponding authors:
Corine H. GeurtsvanKessel (c.geurtsvankessel{at}erasmusmc.nl), Bart L. Haagmans (b.haagmans{at}erasmusmc.nl) and Rory D. de Vries (r.d.devries{at}erasmusmc.nl).
Posted December 29, 2021.
Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
